{"entity":{"id":"nct07748611","kind":"trial","name":"SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial","aka":[],"tldr":"A phase 2 trial of fluorouracil (5-FU), gemcitabine, fOLFIRI (5-FU, leucovorin, irinotecan), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) and other drugs in pancreatic cancer, run by Northwestern University, not yet recruiting.","summary":"SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial is a phase 2, interventional study registered as NCT07748611 by Northwestern University, with a registry enrolment figure of 125 participants, started 2027-02-03 and due to reach its primary completion in 2030-02-03. Interventions recorded: Biospecimen Collection; Computed Tomography; Electronic Health Record Review; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Nab-paclitaxel; Oxaliplatin; Radiation Therapy; Surgical Procedure. Conditions listed: Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma. Primary outcome: Proportion of patients who achieve R0/R1 surgical resection (Cohort A). Pancreatic eligibility wording from the registry: \"* Patients must have histologically confirmed pancreas ductal adenocarcinoma\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07748611","url":"https://clinicaltrials.gov/study/NCT07748611"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt"],"targets":[],"drugs":["fluorouracil","gemcitabine","folfiri","flot","nab-paclitaxel","capox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07748611","phase":"2","setting":"SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study","sponsor":"Northwestern University","enrolled":125,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07748611/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}